<ul><li>Venture capitalists in the biotech industry face challenges in evaluating technological trends, lacking regulatory knowledge, and establishing trust with researchers and the private sector.</li><li>Changes in funding policies, such as capping grant amounts for administrative costs, impact the funding available for research universities, creating an opportunity for new funds to build partnerships with these institutions and poach experts.</li><li>The shift in funding from non-dilutive to dilutive sources pushes biotech founders towards the private sector, making de-risking more difficult. However, investing in companies with lower regulatory burden and rapid scalability can mitigate these challenges.</li><li>Investing in deep technologies within the biotech industry, which have exponential growth potential, has been shown to outperform traditional venture capital, providing a more stable asset class for investors.</li></ul>

BioTech is Broken — Here’s Why

Discover more